Log In Sign up
The largest database of trusted experimental protocols

Midostaurin

Manufactured by LC Laboratories
Visit Supplier
Sourced in United States

Midostaurin is a chemical compound developed for laboratory research purposes. It is a protein kinase inhibitor that can be used to study cellular signaling pathways. The core function of Midostaurin is to inhibit the activity of certain enzymes involved in cell proliferation and survival. However, a detailed description of its intended use or interpretations of its effects are not available within the scope of this response.

Automatically generated - may contain errors

Lab products found in correlation

Quizartinib, by LC Laboratories (3 mentions) Dimethyl sulfoxide (dmso), by Merck Group (3 mentions) Masitinib, by LC Laboratories (2 mentions) Recombinant human serum albumin, by Merck Group (2 mentions) Mifepristone, by Merck Group (2 mentions) Sterile pbs, by Thermo Fisher Scientific (2 mentions) Lyophilized bovine plasma, by Merck Group (2 mentions) Trihexyphenidyl hydrochloride, by Selleck Chemicals (2 mentions) Flt3 s 18 antibody, by Santa Cruz Biotechnology (2 mentions) Rpmi 1640, by Thermo Fisher Scientific (2 mentions) Rpmi 1640, by Merck Group (2 mentions) Sorafenib, by LC Laboratories (2 mentions) Lestaurtinib, by LC Laboratories (2 mentions) Fetal calf serum (fcs), by Thermo Fisher Scientific (2 mentions) Toceranib, by Merck Group (1 mentions) Ibrutinib, by Selleck Chemicals (1 mentions) 4 6 diamidino 2 phenylindole (dapi), by Merck Group (1 mentions) Penicillin streptomycin, by Lonza (1 mentions) Rpmi 1640 medium, by Lonza (1 mentions) Collagenase type 2, by Worthington (1 mentions)

7 protocols using midostaurin

1

Canine Mast Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ibrutinib was obtained from Selleck Chemicals (Houston, Texas), toceranib from Sigma‐Aldrich (St. Louis, Missouri), masitinib and midostaurin from LC laboratories (Woburn, Massachusetts). Stock solutions for all drugs were prepared by dissolving in dimethyl sulfoxide (DMSO) purchased from Sigma‐Aldrich. RPMI 1640 medium, Iscove's modified Dulbecco's medium (IMDM) and antibiotics (penicillin, streptomycin) were purchased from Lonza (Basel, Switzerland), amphotericin B from PAN‐Biotech (Aidenbach, Germany), fetal calf serum (FCS) from Gibco Life Technologies (Carlsbad, California), 3H‐thymidine from PerkinElmer (Waltham, Massachusetts), collagenase type 2 from Worthington (Lakewood, New Jersey) and trypan blue and 4′,6‐diamidino‐2‐phenylindole (DAPI) from Sigma‐Aldrich. DMSO was used as vehicle‐control in all experiments (corresponding to highest drug concentrations) and showed no effects on growth and activation of canine MCs (not shown).
Gamperl S., Stefanzl G., Peter B., Smiljkovic D., Bauer K., Willmann M., Valent P, & Hadzijusufovic E. (2019). Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Veterinary and Comparative Oncology, 17(4), 553-561.
+ Open protocol
+ Expand
2

Inhibitor Compound Preparation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
ARQ 531 was synthesized and provided by ArQule, Inc., (Burlington, MA). Quizartinib, midostaurin, and dasatinib were purchased from LC Laboratories (Woburn, MA). Gilteritinib and venetoclax were purchased from Chemietek (Indianapolis, IN). Entospletinib (GS-9973) was purchased from Selleckchem (Houston, TX). All chemical compounds were dissolved in Dimethyl sulfoxide (DMSO) to obtain a 10 mM stock solution.
Elgamal O.A., Mehmood A., Jeon J.Y., Carmichael B., Lehman A., Orwick S.J., Truxall J., Goettl V.M., Wasmuth R., Tran M., Mitchell S., Lapalombella R., Eathiraj S., Schwartz B., Stegmaier K., Baker S.D., Hertlein E, & Byrd J.C. (2020). Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia. Journal of Hematology & Oncology, 13, 8.
+ Open protocol
+ Expand
3

Cytokine-Mediated Cell Proliferation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Masitinib and midostaurin (PKC412) were purchased from LC Laboratories (Woburn, MA, USA), piceatannol and pimozide from Sigma-Aldrich (St Louis, MO, USA), RDEA119, PD0325901 and NVP-BEZ235 from Selleck (Houston, TX, USA) and RAD001 from ChemieTek (Indianapolis, IN, USA). The antibody-drug conjugate brentuximab vedotin (SGN-35) was kindly provided by Dr P. Veiby and Dr J. V. Garafalo (Millennium Takeda Oncology Company, Cambridge, MA, USA). Stock solutions of drugs were prepared by dissolving in dimethyl sulfoxide (Merck, Darmstadt, Germany). Recombinant human (rh) interleukin (IL)-2 was obtained from ImmunoTools (Friesoythe, Germany), rhIL-4 from Peprotech (Rocky Hill, NJ, USA), rhIL-5 from BD Biosciences (San Jose, CA, USA), rhIL-6 from Novartis (Basel, Switzerland), rhIL-13, rhCD30 ligand, recombinant canine (rc) IL-4, and rc stem cell factor (SCF) from R&D Systems (Minneapolis, MN, USA) and rhSCF from Strathmann Biotech (Hannover, Germany). RPMI 1640 medium and fetal calf serum (FCS) were purchased from PAA Laboratories (Pasching, Austria), 3H-thymidine from Amersham (Buckinghamshire, UK) and the Annexin V-FITC Kit from eBiosciences (San Diego, CA, USA).
Bauer K., Hadzijusufovic E., Cerny-Reiterer S., Hoermann G., Reifinger M., Pirker A., Valent P, & Willmann M. (2016). IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells. Veterinary and comparative oncology, 15(4), 1240-1256.
+ Open protocol
+ Expand
4

Kinase Inhibitor Preparation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Midostaurin and lapatinib were purchased from LC Laboratories (Woburn, Massachusetts). VX-680 was from Symansis (Temecula, California). These inhibitors were dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at −20 °C until use. The final concentration of DMSO in the culture medium and kinase assay mixture was 0.1 %.
Kawai M., Nakashima A., Kamada S, & Kikkawa U. (2015). Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family. Journal of Biomedical Science, 22(1), 48.
+ Open protocol
+ Expand
5

Preparation and Characterization of FLT3 Inhibitor Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
AGP purified from human or bovine plasma (Sigma) was resuspended in unsupplemented RPMI1640 (Gibco) at 10 mg/mL for working stocks. Recombinant human serum albumin (Sigma) was resuspended in RPMI1640 at 100 mg/mL. Lyophilized bovine plasma (Sigma) was reconstituted in sterile PBS (Gibco). TTT-3002 was a generous gift of TauTaTis, Inc. Lestaurtinib, midostaurin, sorafenib, and quizartinib were purchased from LC Laboratories. Each FLT3 TKI was dissolved at 10 mmol/L in 100% sterile-filtered dimethylsulfoxide (DMSO, Sigma). Mifepristone (Sigma) was dissolved at 100 mmol/L in 100% DMSO. Trihexyphenidyl hydrochloride (Selleckchem) was dissolved at 100 mmol/L in methanol. For cell-based assays, working stocks of 10 μmol/L were prepared for each drug in RPMI1640 supplemented with 0.1% DMSO and 0.2% BSA. For spectrophotometric studies, working stocks of 10 μmol/L were prepared using PBS without sera or albumin. ANS (Sigma) was dissolved in DMSO at 200 mmol/L and then diluted to 400 μmol/L with PBS (0.2% DMSO, final). Western blot analysis was performed using the FLT3 S-18 antibody (Santa Cruz Biotechnology) and for other proteins as indicated (Cell Signaling Technology).
Young D.J., Nguyen B., Li L., Higashimoto T., Levis M.J., Liu J.O, & Small D. (2021). A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors. Blood Cancer Discovery, 2(5), 532-547.
+ Open protocol
+ Expand
6

Characterization of FLT3 Inhibitor Interactions

Check if the same lab product or an alternative is used in the 5 most similar protocols
AGP purified from human or bovine plasma (Sigma) was resuspended in unsupplemented RPMI 1640 (Gibco) at 10 mg/mL for working stocks. Recombinant human serum albumin (Sigma) was resuspended in RPMI 1640 at 100 mg/mL. Lyophilized bovine plasma (Sigma) was reconstituted in sterile PBS (Gibco). TTT-3002 was a generous gift of TauTaTis, Inc. (San Diego, CA). Lestaurtinib, midostaurin, sorafenib and quizartinib were purchased from LC Laboratories. Each FLT3 TKI was dissolved at 10 mM in 100% sterile-filtered dimethylsulfoxide (DMSO, Sigma). Mifepristone (Sigma) was dissolved at 100 mM in 100% DMSO. Trihexyphenidyl hydrochloride (Selleckchem) was dissolved at 100 mM in methanol. For cell-based assays, working stocks of 10 μM were prepared for each drug in RPMI 1640 supplemented with 0.1% DMSO and 0.2% bovine serum albumin. For spectrophotometric studies, working stocks of 10 μM were prepared using PBS without sera or albumin. 8-anilinonaphthalene1-sulfonic acid (ANS, Sigma) was dissolved in DMSO at 200 mM, and then diluted to 400 μM with PBS (0.2% DMSO, final). Western analysis was performed using the FLT3 S-18 antibody (Santa Cruz), and for other proteins as indicated (Cell Signaling Technology).
Young D.J., Nguyen B., Li L., Higashimoto T., Levis M.J., Liu J.O, & Small D. (2021). A Method for Overcoming Plasma Protein Inhibition of Tyrosine Kinase Inhibitors. Blood Cancer Discovery, 2(5), 532-547.
+ Open protocol
+ Expand
7

Immortalized Melanocyte Cell Lines with BRAF and MITF

Check if the same lab product or an alternative is used in the 5 most similar protocols
All melanoma cell lines (Supplementary Table S4) were cultured in RPMI (Invitrogen, Vienna, Austria), supplemented with 10% FCS (Invitrogen). Primary human melanocytes transduced with hTERT, p53DD, CDK4(R24C) (primary melanocytes/hTERT/CDK4(R24C)/p53DD) resulting in immortalized melanocytes (HMEL cells), with ectopically expressed BRAFV600E (HMEL-B) or with ectopically expressed BRAFV600E and HA-MITF (HMEL-B/M) have been previously described.14 (link) All utilized small molecule inhibitors are summarized in Supplementary Table S1. MLN8237 was bought from Selleckchem (Houston, TX, USA). Midostaurin and Sunitinib were obtained from LC Laboratories (Woburn, MA, USA).
Pathria G., Garg B., Borgdorff V., Garg K., Wagner C., Superti-Furga G, & Wagner S.N. (2016). Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Cell Death & Disease, 7(3), e2135-.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!